Skip to content

Advertisement

Reproductive Health

What do you think about BMC? Take part in

Open Access

Correction to: Trends in use of and complications from intrauterine contraceptive devices and tubal ligation or occlusion

  • Brandon Howard1Email author,
  • ElizaBeth Grubb2,
  • Maureen J. Lage3 and
  • Boxiong Tang4
Reproductive Health201714:126

https://doi.org/10.1186/s12978-017-0386-2

Received: 11 September 2017

Accepted: 19 September 2017

Published: 6 October 2017

The original article was published in Reproductive Health 2017 14:70

As result of a query from a reader, the authors reviewed the data in Table 2 of the original article [1] and found a number of errors in the prior construction of this data table. A formatting error has also been noticed in Table 1.
Table 1

Rate of IUD insertion and tubal sterilization over time

  

Copper IUD

LNG IUD

Tubal Sterilization

Year

Total N

n (%)

n (%)

n (%)

2006

1,907,748

3454 (0.18)

12,028 (0.63)

14,887 (0.78)

 Age 15 to 19 y

293,354

52 (0.02)

216 (0.07)

38 (0.01)

 Age 20 to 24 y

220,950

330 (0.15)

1257 (0.57)

451 (0.20)

 Age 25 to 34 y

566,152

1735 (0.31)

6230 (1.10)

6642 (1.17)

 Age 35 to 45 y

827,292

1337 (0.16)

4325 (0.52)

7756 (0.94)

2007

1,940,301

3803 (0.20)

16,789 (0.87)

14,769 (0.76)

 Age 15 to 19 y

299,599

79 (0.03)

416 (0.14)

42 (0.01)

 Age 20 to 24 y

224,324

403 (0.18)

1813 (0.81)

444 (0.20)

 Age 25 to 34 y

583,955

1964 (0.34)

8533 (1.46)

6471 (1.11)

 Age 35 to 45 y

832,423

1357 (0.16)

6027 (0.72)

7812 (0.94)

2008

2,001,739

4474 (0.22)

24,276 (1.21)

14,667 (0.73)

 Age 15 to 19 y

308,311

102 (0.03)

690 (0.22)

21 (0.01)

 Age 20 to 24 y

237,192

455 (0.19)

2845 (1.2)

410 (0.17)

 Age 25 to 34 y

615,537

2368 (0.38)

12,545 (2.04)

6473 (1.05)

 Age 35 to 45 y

840,699

1549 (0.18)

8196 (0.97)

7763 (0.92)

2009

2,016,916

4868 (0.24)

24,811 (1.23)

14,881 (0.74)

 Age 15 to 19 y

312,431

93 (0.03)

777 (0.25)

37 (0.01)

 Age 20 to 24 y

237,723

460 (0.19)

2920 (1.23)

394 (0.17)

 Age 25 to 34 y

625,323

2578 (0.41)

12,614 (2.02)

6232 (1.00)

 Age 35 to 45 y

841,439

1737 (0.21)

8500 (1.01)

8218 (0.98)

2010

1,870,675

5246 (0.28)

20,639 (1.10)

13,313 (0.71)

 Age 15 to 19 y

289,736

142 (0.05)

677 (0.23)

37 (0.01)

 Age 20 to 24 y

222,812

551 (0.25)

2101 (0.94)

243 (0.11)

 Age 25 to 34 y

574,702

2782 (0.48)

10,316 (1.8)

5485 (0.95)

 Age 35 to 45 y

783,425

1771 (0.23)

7545 (0.96)

7548 (0.96)

2011

1,909,316

4682 (0.25)

22,035 (1.15)

12,560 (0.66)

 Age 15 to 19 y

295,377

116 (0.04)

762 (0.26)

24 (0.01)

 Age 20 to 24 y

265,891

601 (0.23)

2648 (1.00)

280 (0.11)

 Age 25 to 34 y

575,729

2451 (0.43)

10,694 (1.86)

5102 (0.89)

 Age 35 to 45 y

772,319

1514 (0.20)

7931 (1.03)

7154 (0.93)

P Value for Trend Over Time in the Overall Population

 

<0.0001

<0.0001

<0.0001

The correct version of Table 1 and Table 2 is published in this erratum.
Table 2

Complications and side effects associated with IUD insertion and tubal sterilization over time

 

Copper IUD

LNG IUD

Tubal Sterilization

Complications/Side Effect

n (%)

n (%)

n (%)

Amenorrhea (ICD-9 626.0)

 Total (2006–2011)

2385 (8.99)ab

9077 (7.53)ac

9410 (11.06)bc

 2006

308 (8.92)

941 (7.82)

1638 (11.00)

 2007

381 (10.02)

1278 (7.61)

1614 (10.93)

 2008

412 (9.21)

1873 (7.72)

1700 (11.59)

 2009

448 (9.20)

1845 (7.44)

1658 (11.14)

 2010

452 (8.62)

1518 (7.36)

1429 (10.73)

 2011

384 (8.20)

1622 (7.36)

1371 (10.92)

 P Value

0.0775

0.4191

0.2768

Anemia (ICD-9 280.xx)

 Total (2006–2011)

595 (2.24)b

2832 (2.35)c

2823 (3.32)bc

 2006

67 (1.94)

279 (2.32)

435 (2.92)

 2007

78 (2.05)

386 (2.30)

433 (2.93)

 2008

106 (2.37)

538 (2.22)

492 (3.35)

 2009

119 (2.44)

600 (2.42)

513 (3.45)

 2010

135 (2.57)

512 (2.48)

481 (3.61)

 2011

90 (1.92)

517 (2.35)

469 (3.73)

 P Value

0.1496

0.5243

0.0001

Dysmenorrhea (ICD-9 625.3)

 Total (2006–2011)

723 (2.73)ab

3909 (3.24)ac

3678 (4.32)bc

 2006

90 (2.61)

378 (3.14)

587 (3.94)

 2007

85 (2.24)

566 (3.37)

591 (4.00)

 2008

132 (2.95)

723 (2.98)

598 (4.08)

 2009

139 (2.86)

807 (3.25)

647 (4.35)

 2010

137 (2.61)

692 (3.35)

649 (4.87)

 2011

140 (2.99)

743 (3.37)

606 (4.82)

 P Value

0.6388

0.1234

<0.0001

Heavy Menstrual Bleeding (ICD-9 626.2)

 Total (2006–2011)

1370 (5.16)ab

10,204 (8.46)ac

11,381 (13.38)bc

 2006

204 (5.91)

1048 (8.71)

1687 (11.33)

 2007

198 (5.21)

1406 (8.37)

1750 (11.85)

 2008

224 (5.01)

1846 (7.60)

1922 (13.10)

 2009

256 (5.26)

1992 (8.03)

2045 (13.74)

 2010

261 (4.98)

1881 (9.11)

2006 (15.07)

 2011

227 (4.85)

2031 (9.22)

1971 (15.69)

 P Value

0.3527

<0.0001

<0.0001

Infection (ICD-9 998.5×)

 Total (2006–2011)

15 (0.06)

88 (0.07)c

24 (0.03)c

 2006

4 (0.12)

12 (0.10)

2 (0.01)

 2007

1 (0.03)

14 (0.08)

2 (0.01)

 2008

6 (0.13)

15 (0.06)

7 (0.05)

 2009

2 (0.04)

25 (0.10)

4 (0.03)

 2010

0 (0.00)

14 (0.07)

4 (0.03)

 2011

2 (0.04)

8 (0.04)

5 (0.04)

 P Value

0.0543

0.1255

0.4301

Menorrhagia (ICD-9 627.0)

 Total (2006–2011)

53 (0.20)ab

528 (0.44)ac

640 (0.75)bc

 2006

12 (0.35)

48 (0.40)

88 (0.59)

 2007

6 (0.16)

58 (0.35)

94 (0.64)

 2008

11 (0.25)

84 (0.35)

92 (0.63)

 2009

12 (0.25)

89 (0.36)

119 (0.80)

 2010

8 (0.15)

121 (0.59)

121 (0.91)

 2011

4 (0.09)

128 (0.58)

126 (1.00)

 P Value

0.1181

<0.0001

<0.0001

Ovarian Cyst (ICD-9 620.2)

 Total (2006–2011)

1157 (4.36)ab

6340 (5.26)ac

6063 (7.13)bc

 2006

140 (4.05)

539 (4.48)

1045 (7.02)

 2007

155 (4.08)

786 (4.68)

990 (6.70)

 2008

211 (4.72)

1268 (5.22)

1076 (7.34)

 2009

209 (4.29)

1400 (5.64)

1039 (6.98)

 2010

223 (4.25)

1142 (5.53)

1003 (7.53)

 2011

219 (4.68)

1205 (5.47)

910 (7.25)

 P Value

0.5197

<0.0001

0.0975

Pelvic Inflammatory Disease (ICD-9 614.xx-616.xx)

 Total (2006–2011)

93 (0.35)

334 (0.28)c

319 (0.37)c

 2006

13 (0.38)

40 (0.33)

64 (0.43)

 2007

12 (0.32)

53 (0.32)

66 (0.45)

 2008

23 (0.51)

74 (0.30)

69 (0.47)

 2009

15 (0.31)

60 (0.24)

54 (0.36)

 2010

12 (0.23)

49 (0.24)

41 (0.31)

 2011

18 (0.38)

58 (0.26)

25 (0.20)

 P Value

0.282

0.3727

0.02

Pelvic Pain (ICD-9 625.9, 789.00)

 Total (2006–2011)

3222 (12.15)ab

13,891 (11.52)ac

11,750 (13.81)bc

 2006

384 (11.12)

1395 (11.60)

1987 (13.35)

 2007

466 (12.25)

1915 (11.41)

1997 (13.52)

 2008

519 (11.60)

2729 (11.24)

1976 (13.47)

 2009

627 (12.88)

2897 (11.68)

2117 (14.23)

 2010

661 (12.60)

2419 (11.72)

1881 (14.13)

 2011

565 (12.07)

2536 (11.51)

1792 (14.27)

 P Value

0.1449

0.617

0.0593

Perforation of Uterine Wall (ICD-9 621.8, 665.3)

 Total (2006–2011)

412 (1.55)ab

1558 (1.29)ac

555 (0.65)bc

 2006

40 (1.16)

142 (1.18)

57 (0.38)

 2007

51 (1.34)

176 (1.05)

76 (0.51)

 2008

48 (1.07)

301 (1.24)

91 (0.62)

 2009

88 (1.81)

319 (1.29)

119 (0.80)

 2010

98 (1.87)

307 (1.49)

103 (0.77)

 2011

87 (1.86)

313 (1.42)

109 (0.87)

 P Value

0.0014

0.0023

<0.0001

abcChi square pairwise comparisons between groups with the same superscript, p < 0.05. The pairwise comparisons were done for the total for each complication/side effect across years 2006–2011 and not for the individual years

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Teva Global Medical Affairs
(2)
Teva Global Health Economics & Outcomes Research
(3)
HealthMetrics Outcomes Research
(4)
Teva Global Health Economics & Outcomes Research

Reference

  1. Howard, et al. Trends in use of and complications from intrauterine contraceptive devices and tubal ligation or occlusion. Reprod Health. 2017;14:70. doi:10.1186/s12978-017-0334-1.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement